Welcome to our dedicated page for Vericel SEC filings (Ticker: VCEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vericel Corporation (VCEL) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a NASDAQ-listed issuer, Vericel files annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, along with exhibits and financial statements.
Through these documents, investors can review detailed financial information about Vericel’s business in advanced therapies for sports medicine and severe burn care. The filings describe revenue by product category, including MACI and Burn Care (Epicel and NexoBrid), gross margin, operating expenses, net income or loss, cash and investments, and non-GAAP measures such as adjusted EBITDA. Management explains its use of non-GAAP metrics and provides reconciliations to GAAP results.
Vericel’s Form 8-K filings often furnish press releases announcing quarterly financial results, such as the reports for the quarters ended June 30 and September 30, 2025. These current reports give timely insight into performance trends, business highlights, manufacturing scale-up activities and clinical program updates, including MACI Ankle studies and facility qualification efforts.
Annual and quarterly reports also contain risk factor and forward-looking statement sections that outline uncertainties related to revenue growth, market penetration for MACI, MACI Arthro, Epicel and NexoBrid, manufacturing capacity, reimbursement dynamics, surgeon and burn center adoption, supply chain issues and broader macroeconomic and geopolitical conditions.
On Stock Titan, Vericel’s filings are supplemented with AI-powered summaries that highlight key points from lengthy 10-K and 10-Q documents, explain complex accounting or non-GAAP metrics in plain language, and surface notable items from Form 4 insider transaction reports when available. Real-time updates from EDGAR help users track new VCEL filings as they are posted, while AI-generated overviews make it easier to understand how each filing relates to Vericel’s business in cell therapies and specialty biologics.
Vericel Corp Chief Operating Officer Michael Halpin reported equity compensation activity involving Restricted Stock Units (RSUs) and common stock on February 24, 2026. RSU vesting led to multiple exercises (coded “M”), each for 5,250 units or shares at a price of $0.00 per share, increasing his direct holdings in both RSUs and common stock.
The filing shows common shares withheld in two “F”-coded transactions for 2,486 shares each, at fair market values of $38.09 and $38.25 per share, to satisfy tax withholding obligations. After these transactions, Halpin directly held 26,385 shares of Vericel common stock, along with RSU awards that continue to vest annually through February 2029.
Vericel Corp Chief Legal Officer Sean C. Flynn reported equity award activity on February 24, 2026. He acquired 3,500 and 3,000 shares of common stock through the vesting and conversion of Restricted Stock Units (RSUs) granted in 2025 and 2024, respectively. A total of 1,553 and 1,331 shares of common stock were withheld by Vericel at fair market values of $38.09 and $38.25 per share to cover tax obligations tied to these vestings. After these transactions, Flynn directly owned 7,683 shares of Vericel common stock.
Vericel Corporation focuses on advanced therapies for sports medicine and severe burn care, built around three marketed products: MACI for knee cartilage repair, Epicel for extensive burns, and NexoBrid for enzymatic removal of burn eschar in adults and children.
The company is expanding MACI through the arthroscopic MACI Arthro technique, now FDA‑approved and launched in 2024, and by targeting more surgeons and indications, including a pivotal ankle trial (MASCOT) and a planned UK launch via the MHRA’s recognition pathway. Its new Burlington, Massachusetts facility is intended to become the primary global manufacturing site for MACI and Epicel.
Vericel also grows its burn franchise by pairing Epicel with NexoBrid, supported by exclusive North American rights from MediWound. As of February 19, 2026, 50,763,319 common shares were outstanding, and the aggregate market value of non‑affiliate shares was about $2.1 billion as of June 30, 2025.
Vericel Corporation reported strong fourth-quarter and full-year 2025 results. Total 2025 revenue rose to $276.3 million, up 16% from 2024, driven by MACI revenue of $239.5 million, which grew 21%. Net income increased to $16.5 million, a 59% gain, and full-year gross margin improved to 74%.
In the fourth quarter, revenue grew 23% to $92.9 million, including $84.1 million from MACI, and gross margin reached a record 79%. The company ended 2025 with approximately $200 million in cash and investments and no debt. For 2026, Vericel projects total revenue of $316–$326 million, MACI revenue of $280–$286 million, gross margin of about 75%, and adjusted EBITDA margin of about 27%.
Vericel Corp President and CEO Dominick Colangelo reported multiple equity transactions. On February 19, 2026, he was granted 182,500 stock options and 73,000 restricted stock units (RSUs), both at a stated price of $0 per unit, as part of his compensation.
Footnotes state the options begin vesting on February 19, 2026 and then in equal quarterly installments over four years, while the RSUs vest annually from February 19, 2027 through February 19, 2030. On February 18, 2026, earlier RSUs vested and converted into common stock, and 5,657 shares were withheld at $37.41 per share to cover tax obligations.
Vericel Corp Chief Legal Officer Sean C. Flynn reported multiple equity compensation transactions involving stock options, restricted stock units (RSUs), and common shares. On February 19, 2026, he was granted 35,000 stock options at an exercise price of $0.00 per share and 14,000 RSUs, both held directly. The options begin vesting on February 19, 2026 in equal quarterly installments over four years, while the RSUs vest annually from February 19, 2027 through February 19, 2030.
On February 18, 2026, common shares were acquired upon vesting of RSUs granted on February 18, 2022 and February 17, 2023, with each RSU representing one Vericel common share. In connection with this vesting, 1,490 shares at $36.82 and 1,030 shares at $37.41 were withheld by Vericel to satisfy tax withholding obligations, leaving 4,067 common shares held directly following the last reported transaction.
Vericel Corp Chief Medical Officer Jonathan Mark Hopper reported several equity-related transactions. He received a grant of 35,000 stock options and 14,000 restricted stock units (RSUs) on February 19, 2026, both at no cash cost to him.
On February 18, 2026, previously granted RSUs vested, converting into 3,000 and 2,325 shares of common stock. Of these, 3,000 shares were deferred into phantom stock units under Vericel’s Deferred Compensation Plan, payable later in common shares. The company withheld 982 shares of common stock at a fair market value of $37.41 per share to satisfy tax obligations related to the vesting.
Vericel Corp Chief Financial Officer Mara Joseph Anthony Jr reported several equity-related transactions. On February 19, 2026, he received grants of 46,250 stock options and 18,500 restricted stock units (RSUs), both at a price of $0.00 per share as compensation awards.
On February 18, 2026, RSUs granted in 2022 and 2023 vested, resulting in acquisitions of common stock through derivative exercises and conversions. In connection with these vestings, 1,505 and 809 shares of common stock were disposed of to cover tax withholding obligations at fair market values of $36.82 and $37.41 per share, respectively.
Vericel Corp principal accounting officer Jonathan Siegal reported several equity compensation transactions. On February 19, 2026, he received a grant of 6,600 stock options, which begin vesting on February 19, 2026 in equal quarterly installments over four years, and 6,160 restricted stock units (RSUs), which vest in four annual installments starting February 19, 2027 through 2030.
On February 18, 2026, RSUs previously granted in 2022 and 2023 vested, resulting in the acquisition of 2,500 and 420 shares of common stock, respectively. To cover tax withholding on these vestings, 1,117 shares at a fair market value of $36.82 per share and 188 shares at $37.41 per share were disposed of back to the issuer. Following these transactions, Siegal directly held 3,797 shares of Vericel common stock.
Vericel Corporation’s Chief Operating Officer Michael Halpin reported equity compensation and related share movements. On February 19, 2026, he was granted stock options for 52,500 shares and 21,000 Restricted Stock Units (RSUs), all held directly. These options begin vesting on February 19, 2026 in equal quarterly installments over four years, while the RSUs vest annually from February 19, 2027 through February 19, 2030.
On February 18, 2026, RSUs granted in 2022 and 2023 vested, converting into common stock. In connection with these vestings, the company withheld 2,486 shares at a fair market value of $36.82 per share and 1,812 shares at $37.41 per share to cover tax obligations. These transactions reflect compensation vesting and tax withholding rather than open-market buying or selling.